We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > UTMB

News List

ILIAS Biologics announces the 2nd POC study, showing anti-inflammatory effects of ILB202 on preterm birth prnasia
February 02, 2021
ILIAS Biologics, Inc. announced that its latest research in collaboration with researchers at The University of Texas Medical Brand at Galveston (UTMB) is published in the journal Science Advances.
An in vitro study shows Pfizer-BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with a mutation associated with rapid transmission worldpharmanews
January 11, 2021
Pfizer Inc. and BioNTech SE announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB) that shows the antibodies from people who have received the Pfizer-BioNTech COVID-19 vaccine effectively ...
Moleculin, UTMB partner to study WP1122 for coronavirus pharmaceutical-technology
March 19, 2020
Moleculin Biotech has partnered with the University of Texas Medical Branch at Galveston (UTMB) to test its molecular inhibitors, including WP1122, to treat different viruses ...
Moleculin, UTMB Evaluate Inhibitors for Antiviral Properties contractpharma
March 18, 2020
Moleculin will supply the lead drug candidate, WP1122, and related inhibitors, as well as technical support.